Researchers at First Affiliated Hospital of Anhui Medical University Release New Study Findings on Klebsiella pneumoniae (Ceftazidime-avibactam: Combination therapy versus monotherapy in the challenge of pneumonia caused by carbapenem-resistant...).

The article focuses on comparing the effectiveness of ceftazidime-avibactam (CZA) combination therapy versus monotherapy for treating pneumonia caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). Topics include the clinical and microbiological outcomes of CZA combination therapy, the impact on 14-day and 30-day mortality rates, and the role of carbapenems in enhancing treatment efficacy.